CURRENT CONCEPTS OF COMORBID CONDITIONS IN METABOLICALLY ASSOCIATED FATTY  LIVER DISEASE

dc.contributor.author	Parpibaeva D.А., Buvamukhamedova N.Т.
dc.date.accessioned	2026-11-03T05:15:10Z
dc.date.available	2026-11-03T05:15:10Z
dc.date.issued	2026
dc.identifier.issn	2181-7812
dc.identifier.uri	http://repo.tma.uz/xmlui/handle/1/5674
dc.description.abstract	Current scientific data regarding the role of metabolic abnormalities in the development and progression of metabolically associated fatty liver disease, as well as the assessment of existing approaches to their management, have been analyzed. It is demonstrated that dyslipidemia, insulin resistance, and obesity are not only key risk factors for the development of metabolically associated fatty liver disease but also contribute to increased cardiovascular morbidity and mortality in this patient population. Current non-pharmacological and pharmacological therapeutic strategies aimed at correcting metabolic abnormalities and reducing the risk of disease progression are reviewed.	en_US
dc.language.iso	en_US	en_US
dc.publisher	O'zbekiston, Toshkent (O'zbekiston tibbiyot axborotnomasi) jurnal № 7	en_US
dc.relation.ispartofseries	УДК;616.36-003.826:616-008.9
dc.subject	MAFLD (NAFLD), MASG (NASG), dyslipid emia, cardiometabolic risks, type 2 diabetes mellitus, obesity.	en_US
dc.title	CURRENT CONCEPTS OF COMORBID CONDITIONS IN METABOLICALLY ASSOCIATED FATTY LIVER DISEASE	en_US
dc.type	Article	en_US